These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 17495622)
21. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Pilz G; Wipfler P; Ladurner G; Kraus J Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508 [TBL] [Abstract][Full Text] [Related]
22. Oral disease-modifying treatments for multiple sclerosis: the story so far. Kieseier BC; Wiendl H CNS Drugs; 2007; 21(6):483-502. PubMed ID: 17521228 [TBL] [Abstract][Full Text] [Related]
23. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Wiendl H; Kieseier BC Expert Opin Investig Drugs; 2003 Apr; 12(4):689-712. PubMed ID: 12665424 [TBL] [Abstract][Full Text] [Related]
26. The implications of immunogenicity for protein-based multiple sclerosis therapies. Cohen BA; Oger J; Gagnon A; Giovannoni G J Neurol Sci; 2008 Dec; 275(1-2):7-17. PubMed ID: 18822434 [TBL] [Abstract][Full Text] [Related]
27. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
28. [New approaches in research of therapy of multiple sclerosis]. Hemmer B; Cepok S; Nessler S; Sommer N Med Klin (Munich); 2001 Sep; 96 Suppl 1():23-8. PubMed ID: 11603112 [TBL] [Abstract][Full Text] [Related]
29. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195 [TBL] [Abstract][Full Text] [Related]
30. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Pula JH; Javed A Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177 [TBL] [Abstract][Full Text] [Related]
31. Current therapeutic recommendations in multiple sclerosis. Berger T J Neurol Sci; 2009 Dec; 287 Suppl 1():S37-45. PubMed ID: 20106347 [TBL] [Abstract][Full Text] [Related]
32. The current landscape and unmet needs in multiple sclerosis. Markowitz CE Am J Manag Care; 2010 Sep; 16(8 Suppl):S211-8. PubMed ID: 20873945 [TBL] [Abstract][Full Text] [Related]
33. Early treatment trials with interferon beta in multiple sclerosis. Panitch HS Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392 [TBL] [Abstract][Full Text] [Related]
34. Current evidence and therapeutic strategies for multiple sclerosis. Wingerchuk DM Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987 [TBL] [Abstract][Full Text] [Related]
35. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis]. Correale J; Cristiano E Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177 [TBL] [Abstract][Full Text] [Related]
36. Diagnosis and disease modifying treatments in multiple sclerosis. Zajicek J Postgrad Med J; 2005 Sep; 81(959):556-61. PubMed ID: 16143683 [TBL] [Abstract][Full Text] [Related]
37. Future immunotherapies in multiple sclerosis. Blevins G; Martin R Semin Neurol; 2003 Jun; 23(2):147-58. PubMed ID: 12894380 [TBL] [Abstract][Full Text] [Related]
38. The future of multiple sclerosis therapy. Kieseier BC; Wiendl H; Hartung HP; Stüve O Pharmacol Res; 2009 Oct; 60(4):207-11. PubMed ID: 19717009 [TBL] [Abstract][Full Text] [Related]
39. Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies. Croxford JL; Yamamura T Immunotherapy; 2009 May; 1(3):403-23. PubMed ID: 20635959 [TBL] [Abstract][Full Text] [Related]